On 1 January 2010, the 2010 Prohibited List comes into effect. To give you a chance to familiarise yourself with the list, the World Anti-Doping Agency has published it on their website.

 

From 23 December 2009, if you check your substances on ASADA's website, your search results will be sourced from the 2010 Prohibited List.

 

Some of the key changes from the 2009 Prohibited List include the following:

• The status of salbutamol and salmeterol (used for the treatment of asthma). Therapeutic use of inhaled salbutamol (maximum 1600 micrograms per day) and salmeterol will not be prohibited as of 1 January 2010 with a declaration of use.
• Supplemental oxygen (hyperoxia) will no longer be prohibited.
• The status of platelet-derived preparations (such as Platelet Rich Plasma (PRP), ‘blood spinning’) has been clarified by WADA. It will be prohibited when administered by intramuscular route, but other routes of administration will require a declaration of use.
• Pseudoephedrine will be reintroduced to the Prohibited List and will be prohibited above 150 micrograms per millilitre.

 

Pseudoephedrine

Pseudoephedrine will be reintroduced to the List and will be prohibited above 150 micrograms per millilitre.

Athletes – do not take pseudoephedrine 24 hours prior to or during competition.

There are permitted alternatives which you can take in this time period. Out-of-competition there is no need for a TUE to take pseudoephedrine.

For therapeutic applications in-competition, consider the use of alternative permitted medications upon previous consultation with a physician, or apply for a Therapeutic Use Exemption (TUE).

The threshold level has been established based on the intake of therapeutic doses, defined as a maximum daily dose of 240mg PSE taken either as:

• four (4) daily administrations (one every 4-6 hours) of a 60mg pill (or 2 x 30mg pills), (8 Codral original cold and flu tables in 24 hours), or
• two (2) daily administrations (one every 12 hours) of a 120mg pill, or
• one (1) daily administration of a 240mg pill.

In line with this dosing regimen, the intake, for example, of a single daily dose of 3 x 60mg pills constitutes a supratherapeutic administration that may lead to an Adverse Analytical Finding.

 

Platelet Rich Plasma therapy

If you plan on using a platelet-derived preparation for a muscle injury, you must have an approved TUE prior to the procedure. Injections of platelet-derived preparations into joints will not require a TUE but will require a declaration of use.

You can make a declaration during a testing session by noting the use on the Doping Control Form, or by emailing declaration@asada.gov.au with your sport copied in, detailing athlete’s:

• name
• date of birth
• sport
• address
• substance
• name of treating doctor and
• circumstances of use.